echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > As generics enter the era of micro-profits, where are the new opportunities for pharmaceutical companies?

    As generics enter the era of micro-profits, where are the new opportunities for pharmaceutical companies?

    • Last Update: 2020-11-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical network industry dynamics" recently, the industry has received widespread attention to the news should be the third batch of national tenders, this particularly obvious feature is: the price of domestic pharmaceutical companies, the original pharmaceutical companies have withdrawn.
    , it's no surprise that the price-twisting machine is used to describe the severity of the price cut.
    Such as the very competitive diabetes drug metformin, of which 0.25g specifications of metformin hydrochloride slow release tablets, reported to the low price of nearly 1 cent, Chongqing Core Pharmaceuticals quoted 0.0154 yuan, Shanghai Xinyi Tianping Pharmaceuticals 0.01333 yuan, which is less than 10% of the high effective declared price of 0.2 yuan, the price reduction is far more than 90%.
    In addition, the much-watched West China Sea, its original drug for Pfizer's Wan Aico, Qilu Pharmaceuticals and low prices of 2.08 yuan per tablet (down 92.7%) to become the winning company, the original research drug factory Pfizer out.
    from the above comprehensive point of view, the killing of generic drugs is further white hot.
    generic drugs without technical barriers will gradually return to the level of manufacturing profits, generic drugs "high gross margin" era is coming to an end.
    , industry insiders believe that in the future with the ability to continue the introduction of generic drugs and high research and development investment in innovative pharmaceutical companies will be easier to find survival space.
    fact, in recent years, under the guidance of policy and supervision, the market is driven by the domestic enterprises are constantly upgrading from generic drugs to innovative drugs to explore.
    , however, due to the rapid changes in the policy environment, lack of research and development capabilities and other reasons, leading to even in the field of innovative drugs, there is a certain degree of "high-level duplication of construction" situation.
    addition, coupled with competition and health insurance, so that many varieties of pricing lower than expected, but also let enterprises lack the incentive to innovate.
    but industry insiders believe that high-level repetition is always better than low-level repetition.
    , especially under the influence of policies such as "4 plus 7" with volume procurement, medical insurance control fees and two-vote system, generic drugs have entered the era of micro-profits.
    know that more than 4,000 pharmaceutical companies in China are now basically developing generic drugs, a small number of generics and innovative drugs.
    In another decade more than 4,000 may be reduced to 1000 or less, and this rate depends on policy, prices will fall or expand on the basis of the present, the future can really put the amount of innovative drugs, pharmaceutical companies should focus their resources on innovative drug research and development.
    fact, in recent years, the transition to innovative drugs has gradually become the industry consensus.
    Zhengda Tianqing related to the person in charge has said that, with the expansion of the national volume of procurement, the future of generic drugs into the era of micro-profits, and high-tech barriers to generic drugs and innovative drugs will become the direction of research and development of pharmaceutical companies.
    , 70% of the company's new 2019 products are innovative drugs.
    note that generics are slightly leighemic, but that doesn't mean that the innovative drug circuit is the way to go.
    will be an important challenge in the transformation path of pharmaceutical companies.
    industry experts point out that if companies take the path of innovation, it is essentially limited to research and development talent and research and development investment two important factors.
    this requires enterprises not only to have a good top-level design, the right direction of continuous power, but also need the enterprise's internal skills and their own perfect system.
    , but overall, there is still a lot of clinical demand that has not yet been met, which is the potential future profit growth point for innovative pharmaceutical companies.
    the future, in the volume procurement to promote the pharmaceutical industry to increase the development of high-end generic drugs and innovative pharmaceutical field investment, accelerate industrial upgrading, pharmaceutical companies follow the policy orientation, adjust the strategic layout of products, will become the top priority of enterprise development.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.